Analysts take a look at Horizon Pharma Public Limited Company (NASDAQ:HZNP) having this to say.

February 15, 2018 - By Ivan Hodges

 Analysts take a look at Horizon Pharma Public Limited Company (NASDAQ:HZNP) having this to say.
Investors sentiment increased to 1 in 2017 Q3. Its up 0.08, from 0.92 in 2017Q2. It increased, as 33 investors sold Horizon Pharma Public Limited Company shares while 50 reduced holdings. 28 funds opened positions while 55 raised stakes. 132.29 million shares or 1.03% more from 130.94 million shares in 2017Q2 were reported.
Hudson Bay Management Ltd Partnership has invested 0.07% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Deutsche Bankshares Ag holds 2.16M shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 5,210 shares. Tower Rech Cap Limited Liability Company (Trc) invested in 0.02% or 16,463 shares. Bank Of Montreal Can accumulated 2,241 shares. Capital Guardian Trust Communications has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Amer Century holds 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP) or 316,729 shares. Profund Advsr Ltd Limited Liability Company, a Maryland-based fund reported 12,855 shares. Massachusetts Svcs Co Ma has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 80,507 shares. Deerfield Mngmt Communication holds 3.95% or 6.92M shares in its portfolio. Aqr Capital Ltd Co stated it has 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Guggenheim Ltd Liability holds 0.01% or 297,062 shares. Geode Cap Mngmt Lc, a Massachusetts-based fund reported 1.49M shares. Commonwealth Equity Ser Inc accumulated 16,013 shares or 0% of the stock. Point72 Asset Mgmt Limited Partnership reported 2.81M shares.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Horizon Pharma had 55 analyst reports since September 9, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Buy” rating and $18.0 target in Tuesday, September 26 report. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Buy”. On Tuesday, November 7 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Tuesday, May 3 by Mizuho. The rating was maintained by Jefferies with “Buy” on Friday, October 13. The firm has “Buy” rating given on Monday, December 14 by Mizuho. As per Tuesday, February 28, the company rating was maintained by Mizuho. UBS maintained the stock with “Buy” rating in Thursday, November 30 report. The stock has “Buy” rating by Piper Jaffray on Friday, July 14. Citigroup upgraded Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Monday, November 28 to “Buy” rating. Below is a list of Horizon Pharma Public Limited Company (NASDAQ:HZNP) latest ratings and price target changes.

30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
30/11/2017 Broker: UBS Rating: Buy New Target: $20.0 Maintain
10/11/2017 Broker: Cowen & Co Rating: Buy New Target: $22.0 Maintain
07/11/2017 Broker: Jefferies Rating: Buy Old Target: $16 New Target: $21 Maintain
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $18.0 Maintain
20/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20.0 Maintain
13/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
13/10/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain

The stock decreased 0.50% or $0.07 during the last trading session, reaching $14.04. About 538,615 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since February 15, 2017 and is downtrending. It has underperformed by 44.83% the S&P500.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.30 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Seekingalpha.com which released: “Horizon Pharma Plc (HZNP) Q3 2017 Results – Earnings Call Transcript” on November 06, 2017, also Globenewswire.com with their article: “Horizon Pharma plc to Present at the 36th Annual JP Morgan Healthcare Conference” published on December 18, 2017, Seekingalpha.com published: “Horizon Pharma Plc (HZNP) Q2 2017 Results – Earnings Call Transcript” on August 07, 2017. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Globenewswire.com and their article: “Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers …” published on January 08, 2018 as well as Seekingalpha.com‘s news article titled: “Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold” with publication date: December 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.